PHATHOM PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $1.39 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2026-02-26
- PHATHOM PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2025 was $1.39M, a 20.01% decline from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2024 was $1.74M, a 41.47% decline from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2023 was $2.97M, a 21.12% increase from fiscal 2022.
- PHATHOM PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2022 was $2.45M, a 16.85% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.39M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $1.74M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $2.97M 10-K · filed 2025-03-06 | -$2.97M 10-K · filed 2024-03-07 |
| 2022-12-31 | $2.45M 10-K/A · filed 2024-06-14 | |
| 2021-12-31 | $2.95M 10-K · filed 2023-02-28 | |
| 2020-12-31 | $3.05M 10-K · filed 2022-03-01 | |
| 2019-12-31 | $697.00K 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |